Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Legend Biotech

Evaluate

May 04, 2023

The quiet resurgence of Cellular Biomedicine

Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.

Thumbnail
April 19, 2023

After Mariposa a Carvykti leak brings J&J better news

No news is bad news for the Mariposa trial, J&J’s bid for market share in lung cancer, but Carvykti turns the frown upside down.

Article image
Vantage logo
April 17, 2023

AACR 2023 – Regeneron tries again in multiple myeloma

If at first you don’t succeed... Regeneron follows the underwhelming linvoseltamab with something it hopes will be better.

Article image
Vantage logo
February 23, 2023

Astra buys itself a second shot at the Claudin18.2 goal

Article image
Vantage logo
January 27, 2023

What Abecma does Carvykti might do better

Article image
Vantage logo
December 21, 2022

Remarkably, interest in BCMA continues

But, as Celyad bows out, how do you compete in a field as crowded as this?

Article image
Vantage logo
November 17, 2022

Astellas gives the Claudin18.2 pipeline a boost

Article image
Vantage logo
October 19, 2022

J&J’s $5bn projects have much to prove

The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.

Article image
Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Carvykti casts a long shadow

Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.

Article image
Vantage logo
April 21, 2022

Jumping aboard the Claudin18.2 bandwagon

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up